Combining Capecitabine and Temsirolimus Safe and Effective in Patients With Advanced Malignancies - Med India

Combining capecitabine and temsirolimus for treating advanced malignancies is effective and can safely be given to patients, according to a phase I study looking into whether the combination of the two agents is safe for patients. In addition ...

Phase I study of temsirolimus, capecitabine proves safe; positive survival trend seen - medicalxpress.com

A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients. In addition, the Georgetown Lombardi Comprehensive Cancer Center ...

ASCO Preview: Eight Cancer Drugs to Watch at the Big Show - Xconomy

These women had previously gotten Herceptin, and were randomly assigned to get either T-DM1 or a combo of GlaxoSmithKline’s lapatinib (Tykerb) and capecitabine (Xeloda) chemotherapy. Partly because this drug is working against a high-profile ...

Undaunted by Wall Street “Penalty Box,” Keryx Focuses on Kidney Drug - Xconomy

In an earlier trial with 38 patients, the drug looked promising in combination with a Roche product called capecitabine (Xeloda): It extended median survival from seven to 17 months compared with capecitabine alone. But those results couldn’t ...

Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer - msnbc.com

Testing for HER2 expression is required; HER2+ patients must have received and progressed on trastuzumab (Herceptin ®; Hoffmann La Roche, Inc.).  In this "all-oral" chemotherapy program, eligible patients will receive capecitabine (Xeloda ...

5 Biotech Stocks At Rock Bottom Price With Takeover Possibility - Seekingalpha.com

Reason for the Downfall On April 2, 2012, Keryx announced that the Phase 3 "X-PECT" (Xeloda & Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine (KRX-0401) & capecitabine (Xeloda) in patients with refractory advanced ...

Aeterna Zentaris Regains North American Rights to Akt Inhibitor from Keryx - Genetic Engineering News

Termination of the firms’ licensing agreement comes just over a month after Aeterna Zentaris reported that a Phase III colorectal cancer trial evaluating perifosine in combination with capecitabine (Xeloda) failed to meet its primary endpoint ...

Aeterna Zentaris Reports First Quarter 2012 Financial and Operating Results - Phramalive.com

Perifosine (Oral Akt Inhibitor) Japanese partner, Yakult Honsha, initiated a Phase 1/2 trial in Japan with perifosine + capecitabine in refractory advanced colorectal cancer. Subsequent to quarter-end, topline results for the Phase 3 "X-PECT" (Xeloda  ...

Diagnosed Nov 2009 - American Cancer Society

(Still have a little chemo brain!LOL) I went thru 4 rounds of Docetaxel, Capecitabine and bevacizumab. The 4 rounds of AC with bevacizumab. Then a double mastecomy. Then 5 rounds again of the same 2 chemo cocktails. So from Nov of 09 to Jan of 11 I was out of commission.